Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Sponsor: GlaxoSmithKline
Listed as NCT01610414, this PHASE3 trial focuses on Herpes Zoster and remains completed. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Dec 2017 [monthly]
Completed PHASE3
-
May 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Apr 2017 — May 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Airdrie, United Kingdom , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Athens, Greece , Aurora, United States , Aviano (PN), Italy , Badalona/Barcelona, Spain , Barcelona, Spain , Bayreuth, Germany and 136 more locations